Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance

SIMPLE SUMMARY: To ameliorate the situation for kidney cancer patients and to broaden the application of available drugs, we initiated this research to enhance the anti-cancer activity through combination treatment. There is an unmet need for innovative treatment strategies and optimized drug combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Rausch, Magdalena, Weiss, Andrea, Zoetemelk, Marloes, Piersma, Sander R., Jimenez, Connie R., van Beijnum, Judy R., Nowak-Sliwinska, Patrycja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693411/
https://www.ncbi.nlm.nih.gov/pubmed/33126775
http://dx.doi.org/10.3390/cancers12113172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693411/
https://www.ncbi.nlm.nih.gov/pubmed/33126775
http://dx.doi.org/10.3390/cancers12113172

Ejemplares similares